Monitor upcoming clinical trial results for TNX-1700 and TNX-4700, as positive preclinical data suggests potential for future development, but clinical validation is needed.
Price Chart
Executive Summary
Tonix Pharmaceuticals presented preclinical data at the AACR 2026 conference showing that TNX-1700 reversed aging-associated gastric inflammation and attenuated tumor progression in mouse models, while TNX-4700 demonstrated potent anti-BTLA activity. The data supports the potential of these immuno-oncology candidates for cancer treatment.
Key Facts
- Presented preclinical data on TNX-1700 at AACR 2026 showing it reversed aging-associated gastric inflammation and attenuated tumor progression in mouse models
- TNX-1700 demonstrated dose-independent, linear pharmacokinetics in animals
- TNX-4700 demonstrated potent, high-affinity binding and functional antagonism of BTLA
- TNX-4700 has reduced FcgRI binding and no binding to FcgRIIB compared to antibody control
Financial Impact
No immediate financial impact as data is preclinical
Risk Factors
- Preclinical results may not translate to human efficacy
- Long development timeline for immuno-oncology candidates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001999371-26-008771 |
| Exhibit: ex99-01.htm | 0001999371-26-008771 |
| Exhibit: ex99-02.htm | 0001999371-26-008771 |
| Exhibit: ex99-03.htm | 0001999371-26-008771 |
| Document: 0001999371-26-008771-index-headers.html | 0001999371-26-008771 |
| Document: 0001999371-26-008771-index.html | 0001999371-26-008771 |
| Document: 0001999371-26-008771.txt | 0001999371-26-008771 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | Press Release | $5.73 | awaiting T+20 | — | $5.43 (−5.24%) |
Oct 15, 2026 12d ago | 8-K | $6.42 | awaiting T+20 | — | $5.43 (−15.42%) |
Oct 2, 2026 24d ago | 8-K | $8.07 | awaiting T+20 | — | $5.43 (+32.71%) |
Sep 22, 2026 5w ago | 8-K | $10.59 $5.78 | ▼ −45.42% | ▼ −44.86% | $5.43 (−48.73%) |
Sep 8, 2026 7w ago | 8-K | $13.16 $7.70 | ▼ −41.49% | ▼ −43.46% | $5.43 (−58.74%) |
Aug 10, 2026 11w ago | 8-K | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.43 (−56.87%) |
Aug 10, 2026 11w ago | Press Release | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.43 (−56.87%) |
Aug 3, 2026 12w ago | 8-K | $10.67 $14.10 | ▲ +32.15% | ▲ +30.91% | $5.43 (−49.11%) |
Jul 27, 2026 13w ago | Press Release | $10.37 $12.45 | ▲ +20.06% | ▲ +16.76% | $5.43 (−47.64%) |
Jul 13, 2026 15w ago | 8-K | $11.71 $12.59 | ▲ +7.56% | ▲ +4.38% | $5.43 (−53.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers